ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0892 • ACR Convergence 2020

    Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis

    Sergio Schwartzman1, David Sandoval2, Andris Kronbergs2, Jeffrey Lisse3, Himanshu Patel3, Wen Xu3, Soyi Liu-Leage3, Marina Magrey4, Helena Marzo-Ortega5 and Denis Poddubnyy6, 1Weill Cornell Medical College, New York, NY, 2Eli Lilly and Company, Indianapolis, 3Eli Lilly and Company, Indianapolis, IN, 4Case Western Reserve University School of Medicine, Cleveland, OH, 5The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, 6Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum  (ankylosing spondylitis and…
  • Abstract Number: 0891 • ACR Convergence 2020

    Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2

    Kristian Reich1, Jan Dutz2, Peter Foley3, Diamant Thaçi4, Ron Vender5, Michael Song6, Megan Miller6, Yin Yu6, Shu Li7, Yaung-Kaung Shen6 and April W. Armstrong8, 1Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany, 2Vancouver General Hospital, Vancouver, Canada, 3University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, Australia, 4Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 5McMaster University, Hamilton, Canada, 6Janssen Research & Development, LLC, Spring House, 7Janssen Scientific Affairs, LLC, Horsham, 8Keck School of Medicine of University of Southern California, Los Angeles, CA

    Background/Purpose: Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1 and VOYAGE 2 are two ongoing Phase 3, randomized, double-blind,…
  • Abstract Number: 0897 • ACR Convergence 2020

    Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept

    Xenofon Baraliakos1, Annette Szumski2, Kenneth Kwok3 and Bonnie Vlahos4, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2Syneos Health, Princeton, 3Pfizer, New York, NY, 4Pfizer, Collegeville, PA

    Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…
  • Abstract Number: 0896 • ACR Convergence 2020

    Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs

    Iain McInnes1, William Tillett2, Philip Mease3, Kurt de Vlam4, Louis Bessette5, Ralph Lippe6, Anna Maniccia7, Patrick Zueger7, Dai Feng7, Koji Kato8 and Andrew Östör9, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 5Laval University, Quebec, Canada, 6AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 7AbbVie Inc., North Chicago, IL, 8AbbVie Inc, North Chicago, IL, 9Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…
  • Abstract Number: 0902 • ACR Convergence 2020

    Impact of Dose Escalation of Secukinumab in Patients with Psoriatic Arthritis in Real-World Setting

    Maria Martin-Lopez1, Beatriz Joven2 and Jose Luis Pablos1, 1Hospital 12 de Octubre, Madrid, Spain, 2Hospital Universitario 12 de Octubre, Madrid, Spain

    Background/Purpose: Secukinumab (SEC) has provided efficacy in clinical trials in patients with psoriatic arthritis (PsA). In PsA patients, a gain in response has been suggested…
  • Abstract Number: 0904 • ACR Convergence 2020

    Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks

    John Reveille1, Proton Rahman2, David Sandoval3, Talia Muran3, Andris Kronbergs3, Rebecca Bolce3, Vladimir Geneus3, Theresa Hunter3, Soyi Liu-Leage4, Martin Rudwaleit5, Jose Maldonado-Cocco6 and Filip Van den Bosch7, 1Department of Internal Medicine, University of Texas, Houston, TX, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Eli Lilly and Company, Indianapolis, 4Eli Lilly and Company, Indianapolis, IN, 5Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, 6University of Buenos Aires School of Medicine, Buenos Aires, Argentina, 7Ghent University Hospital, Ghent, Belgium

    Background/Purpose: Tumor necrosis factor inhibitors (TNFis) are effective treatments for radiographic axial spondyloarthritis (r-axSpA), but may be less effective in patients (pts) without elevated C-reactive…
  • Abstract Number: 0899 • ACR Convergence 2020

    Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial

    Denis Poddubnyy1, Effie Pournara2, Agnieszka Zielinska3, Asta Baranauskaite4, Alejandro Muñoz Jiménez5, Sanchayita Sadhu6, Barbara Schulz2, Michael Rissler2, Chiara Perella2 and Helena Marzo-Ortega7, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Medycyna Kliniczna, Warszawa, Poland, 4Lithuanian University of Health Sciences, Kaunas, Lithuania, 5H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 6Novartis Healthcare Private Limited, Hyderabad, Telangana, India, 7The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom

    Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…
  • Abstract Number: 0894 • ACR Convergence 2020

    Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study

    Stanley Cohen1, Justus Fiechtner2, Philip Mease3, Jeffrey Kaine4, Arthur Kavanaugh5, Yi-Lin (Irene) Cheng6, Claire Chou6, Ting-Ying Cheng7, Shih-Yao Lin6 and Mark Genovese8, 1University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, 2Michigan State University, Grand Rapids,, MI, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4Sarasota Arthritis Research Center, Sapphire, NC, 5UC San Diego Health System, San Diego, CA, 6AltruBio, Taipei, Taiwan (Republic of China), 7AltruBio, Redwood City, CA, 8Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.…
  • Abstract Number: 0907 • ACR Convergence 2020

    Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)

    Laura Coates1, Dafna Gladman2, Filip Van den Bosch3, Philip Helliwell4, Anna Rychlewska-Hańczewska5, Mykola Stanislavchuk6, Leen Gilles7, Lien Gheyle7, Ke Liu8, Mona Trivedi8, Muhsen Alani9, Robin Besuyen10 and Philip Mease11, 1University of Oxford, Oxford, United Kingdom, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Ghent University Hospital, Ghent, Belgium, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Ai Centrum Medyczne, Poznań, Poland, 6National Pirogov Memorial Medical University, Vinnytsya, Ukraine, 7Galapagos NV, Mechelen, Belgium, 8Gilead Sciences, Inc., Foster City, CA, 9Gilead Sciences, Inc. and University of Washington, Foster City, CA, 10Galapagos BV, Leiden, Netherlands, 11Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P,…
  • Abstract Number: 0910 • ACR Convergence 2020

    Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2

    Philip Mease1, Laura Coates2, Filip Van den Bosch3, Philip Helliwell4, Dafna Gladman5, Leen Gilles6, Lien Gheyle6, Mona Trivedi7, Muhsen Alani8 and Robin Besuyen9, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2University of Oxford, Oxford, United Kingdom, 3Ghent University Hospital, Ghent, Belgium, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 6Galapagos NV, Mechelen, Belgium, 7Gilead Sciences, Inc., Foster City, CA, 8Gilead Sciences, Inc. and University of Washington, Foster City, CA, 9Galapagos BV, Leiden, Netherlands

    Background/Purpose: EQUATOR (NCT03101670) was a 16-week, Phase 2, double-blind, randomized placebo-controlled trial of filgotinib for PsA. At Week 16, placebo-treated patients could switch to filgotinib…
  • Abstract Number: 0911 • ACR Convergence 2020

    Impact of Filgotinib on Structural Lesions in the Sacroiliac Joints at 12 Weeks in Patients with Active Ankylosing Spondylitis: Correlation with Clinical Endpoints

    Walter Maksymowych1, Mikkel Østergaard2, Robert Landewé3, William Barchuk4, Ke Liu4, Chantal Tasset5, Leen Gilles5, Thijs Hendrikx6, Robin Besuyen6 and Xenofon Baraliakos7, 1University of Alberta, Edmonton, AB, Canada, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Galapagos BV, Leiden, Netherlands, 7Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

    Background/Purpose: In the Phase 2 TORTUGA trial (NCT03117270), the oral, selective Janus kinase 1 inhibitor filgotinib reduced inflammation in patients with active ankylosing spondylitis (AS),…
  • Abstract Number: 0906 • ACR Convergence 2020

    Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study

    Atul Deodhar1, Laure Gossec2, Philip Mease3, Jason Coarse4, Heather Edens5, Natasha de Peyrecave6, Deepak Assudani6, Barbara Ink7 and Christopher Ritchlin8, 1Oregon Health & Science University, Portland, OR, 2Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4UCB Pharma, Raleigh, NC, 5UCB Pharma, Smyrna, GA, 6UCB Pharma, Slough, United Kingdom, 7UCB Pharma, Slough, 8Department of Medicine, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
  • Abstract Number: 0914 • ACR Convergence 2020

    Serious Infections in People with Systemic Sclerosis: A National U.S. Study

    Jasvinder Singh1 and John Cleveland1, 1University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To study incidence, time-trends and outcomes of serious infections in systemic sclerosis (SSc).Methods: We used the 1998-2016 U.S. National Inpatient Sample data. We examined…
  • Abstract Number: 0909 • ACR Convergence 2020

    Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study

    Iain McInnes1, Philip Mease2, Dafna Gladman3, Laura Coates4, Peter Nash5, Alexis Ogdie6, Frank Behrens7, Philippe Goupille8, Arthur Kavanaugh9, Ruvie Martin10, Erhard Quebe-Fehling11 and Corine Gaillez11, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of Oxford, Oxford, United Kingdom, 5School of Medicine Griffith University, Brisbane, Queensland, Australia, 6University of Pennsylvania, Philadelphia, PA, 7CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 8CHU Tours, department of rheumatology, Tours, France, 9Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
  • Abstract Number: 0801 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Joe Zhuo2, Amy Schrader1, Nicole Middaugh1, Page Moore1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
  • « Previous Page
  • 1
  • …
  • 685
  • 686
  • 687
  • 688
  • 689
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology